---
title: "Regeneron (REGN) Gets a Hold from Scotiabank"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296499616.md"
description: "Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron (REGN) with a $770 price target. This follows similar Hold ratings from Leerink Partners, while BMO Capital simultaneously issued a Buy rating for the stock."
datetime: "2026-08-20T13:25:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296499616.md)
  - [en](https://longbridge.com/en/news/296499616.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296499616.md)
generator: "portal-rs"
---

# Regeneron (REGN) Gets a Hold from Scotiabank

Scotiabank analyst Louise Chen maintained a Hold rating on Regeneron today and set a price target of $770.00.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Chen covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Gilead Sciences, and Merck & Company. According to TipRanks, Chen has an average return of 7.4% and a 53.78% success rate on recommended stocks. 

In addition to Scotiabank, Regeneron also received a Hold from Leerink Partners’s David Risinger in a report issued on August 17. However, on the same day, BMO Capital maintained a Buy rating on Regeneron (NASDAQ: REGN).

### Related Stocks

- [REGN.US](https://longbridge.com/en/quote/REGN.US.md)
- [BNS.US](https://longbridge.com/en/quote/BNS.US.md)
- [JNJ.US](https://longbridge.com/en/quote/JNJ.US.md)
- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [BMO.US](https://longbridge.com/en/quote/BMO.US.md)

## Related News & Research

- [$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/296847570.md)
- [Does First-in-Class FOP Drug Approval Transform the Bull Case For Regeneron Pharmaceuticals (REGN)?](https://longbridge.com/en/news/296702017.md)
- [Regeneron Stock (REGN) Buckling as Shareholders Sue Over Cancer Drug Claims](https://longbridge.com/en/news/296616209.md)
- [Regeneron podcast turns science into immersive experience](https://longbridge.com/en/news/296758441.md)
- [04:39 ETRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - REGN](https://longbridge.com/en/news/296589805.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**